Phaseolus max

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• Alzheimer dementia [Insufficient Evidence]
• asthma [Insufficient Evidence]
• BPH [Possibly Ineffective]
• cancer prevention, breast [Possibly Effective]
• cancer prevention, cervical [Insufficient Evidence]
• cancer prevention, colorectal [Possibly Ineffective]
• cancer prevention, endometrial [Insufficient Evidence]
• cancer prevention, gastric [Insufficient Evidence]
• cancer prevention, lung [Insufficient Evidence]
• cancer prevention, thyroid [Insufficient Evidence]
• cardiovascular dz prevention [Insufficient Evidence]
• child growth [Insufficient Evidence]
• CKD [Possibly Effective]
• cognitive function [Insufficient Evidence]
• cognitive impairment [Insufficient Evidence]
• colic [Insufficient Evidence]
• Crohn dz [Insufficient Evidence]
• diabetes mellitus [Possibly Effective]
• diabetic nephropathy [Insufficient Evidence]
• diarrhea [Possibly Effective]
• dyspepsia [Insufficient Evidence]
• exercise-induced muscle soreness [Possibly Ineffective]
• fibromyalgia [Insufficient Evidence]
• galactosemia [Possibly Effective]
• hepatitis C [Insufficient Evidence]
• hot flashes, androgen deprivation tx-assoc. [Insufficient Evidence]
• hot flashes, breast CA-assoc. [Possibly Ineffective]
• HTN [Possibly Effective]
• hyperlipidemia [Possibly Effective]
• IBS [Insufficient Evidence]
• lactose intolerance [Possibly Effective]
• mastalgia [Insufficient Evidence]
• menopausal sx [Possibly Effective]
• menstrual migraine prophylaxis [Insufficient Evidence]
• metabolic syndrome [Possibly Effective]
• muscle strength [Possibly Effective]
• neonatal jaundice prevention [Insufficient Evidence]
• nonalcoholic fatty liver dz [Insufficient Evidence]
• obesity [Insufficient Evidence]
• osteoarthritis [Insufficient Evidence]
• osteoporosis [Possibly Effective]
• overall mortality [Insufficient Evidence]
• polycystic ovary syndrome [Insufficient Evidence]
• postmenopausal conditions [Insufficient Evidence]
• premenstrual syndrome [Insufficient Evidence]
• preterm labor prevention [Insufficient Evidence]
• prostate CA [Insufficient Evidence]
• rheumatoid arthritis [Insufficient Evidence]
• sarcopenia [Insufficient Evidence]
• stroke [Insufficient Evidence]
• vaginal atrophy [Insufficient Evidence]
• wrinkled skin [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Special Note

[formulation clarification]

Info: may incl. whole soy foods, isolated soy protein, soy fiber or soy extracts; soy products contain isoflavone phytoestrogens, such as genistein and daidzein

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

asthma

[Insufficient Evidence]

Dose: 250 mcg genistein PO for every 1000 kcal consumed

cognitive function

[Insufficient Evidence]

Dose: 60-110 mg soy isoflavones PO qd

diabetes mellitus

[Possibly Effective]

Dose: 300 mg Touchi extract PO tid; Alt: 40-161 mg soy isoflavones PO qd; 0.3 g/kg/day soy protein PO in divided doses starting 24-28 wk gestation

diarrhea, peds pts

[Possibly Effective]

Dose: soy fiber-fortified formula PO 3-8x/day; Info: individualize dose; soy protein content 1.8-2 g/dL of soy formula

hepatitis C

[Insufficient Evidence]

Dose: 32 g soy protein PO qd

HTN

[Possibly Effective]

Dose: 18-40 g soy protein PO qd; Alt: 4.5 g black soy peptide PO qd

hyperlipidemia

[Possibly Effective]

Dose: 20-50 g soy protein PO qd

IBS

[Insufficient Evidence]

Dose: 40 mg soy isoflavones PO qd

CKD

[Possibly Effective]

Dose: 700-800 mg/kg/day soy protein PO in divided doses; Max: 800 mg/kg/day

mastalgia

[Insufficient Evidence]

Dose: 17 g soy milk PO bid

menopausal sx

[Possibly Effective]

Dose: 34-200 mg/day soy isoflavones PO divided qd-tid

menstrual migraine prophylaxis

[Insufficient Evidence]

Dose: 60 mg soy isoflavones PO qd; Info: used w/ dong quai and black cohosh

metabolic syndrome

[Possibly Effective]

Dose: 30 g soy nut or soy protein PO qd; Info: dietary replacement of red meat

muscle strength

[Possibly Effective]

Dose: 1.2-1.5 g/kg/day soy protein PO in divided doses; Alt: 25 g soy protein PO qd

neonatal jaundice prevention

[Insufficient Evidence]

Dose: 0.3 g/kg/day soy protein PO in divided doses; Start: 24-28 wk gestation

obesity

[Insufficient Evidence]

Dose: 4.5 g black soy peptide PO qd; Alt: 100 g soy fiber PO qd; 52 g soy protein PO bid

osteoarthritis

[Insufficient Evidence]

Dose: 40 g soy protein PO qd

osteoporosis

[Possibly Effective]

Dose: 50-90 mg soy isoflavones PO qd

overall mortality

[Insufficient Evidence]

Dose: 60 g soy PO qd

polycystic ovary syndrome

[Insufficient Evidence]

Dose: 50 mg soy isoflavones PO qd

premenstrual syndrome

[Insufficient Evidence]

Dose: 68 mg soy isoflavones PO qd

prostate CA, tx or prevention

[Insufficient Evidence]

Dose: 8 oz soy milk PO tid; Alt: 107-117 mg soy isoflavones PO qd

sarcopenia

[Insufficient Evidence]

Dose: 16 g soy protein PO qd

vaginal atrophy

[Insufficient Evidence]

Dose: 1 g PV qd; Info: 4% isoflavone vaginal gel

wrinkled skin

[Insufficient Evidence]

Dose: 40 mg soy isoflavones PO qd; Alt: apply soy based moisturizer topically bid